Wells Fargo & Company MN Sells 67,546 Shares of Grifols, S.A. (NASDAQ:GRFS)

Wells Fargo & Company MN reduced its holdings in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 9.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 625,453 shares of the biotechnology company's stock after selling 67,546 shares during the quarter. Wells Fargo & Company MN owned approximately 0.09% of Grifols worth $4,653,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. R Squared Ltd acquired a new position in Grifols during the fourth quarter worth $28,000. GAMMA Investing LLC grew its holdings in Grifols by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 1,527 shares during the period. Blue Trust Inc. increased its position in Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after buying an additional 4,970 shares during the last quarter. Envestnet Portfolio Solutions Inc. acquired a new stake in shares of Grifols during the 4th quarter worth about $77,000. Finally, Raymond James Financial Inc. bought a new stake in Grifols in the 4th quarter valued at $91,000.

Grifols Price Performance

GRFS stock traded up $0.03 during midday trading on Thursday, reaching $7.22. The company had a trading volume of 881,355 shares, compared to its average volume of 1,205,038. The company has a market capitalization of $4.96 billion, a price-to-earnings ratio of 6.16 and a beta of 0.41. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols, S.A. has a 1-year low of $5.79 and a 1-year high of $9.96. The stock has a 50 day moving average price of $7.48 and a 200-day moving average price of $7.78.

Analysts Set New Price Targets

Separately, Morgan Stanley began coverage on shares of Grifols in a research report on Wednesday, February 12th. They issued an "overweight" rating for the company.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.